Skip to content

Author

David G. Kiely

We have 6 of 28 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Dapagliflozin in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: the DAPAH randomized controlled trial

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce mortality in left heart failure. In pre-capillary pulmonary hypertension (PH), preclinical data suggest SGLT2i may improve right ventricular (RV) function through metabolic modulation, reduced perivascular inflammation, and inhibition of vascular remodelin...

M. Ersboll, J. Kjaergaard, F. Gustafsson et al. · 0 citations
Aug 2026

Dapagliflozin in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: The DAPAH randomized controlled trial.

BACKGROUND SGLT2 inhibitors (SGLT2i) reduce mortality in left heart failure. In pulmonary arterial hypertension (PAH), preclinical data suggest SGLT2i improve right ventricular function through metabolic modulation and inhibition of vascular remodeling via smooth muscle cell pathways. The DAPAH trial evaluated whether...

M. Ersbøll, J. Kjærgaard, K. Waidtløw et al. · 1 citation
Open access Oct 2026

Automated CMR Quantification of Pulmonary Artery Size-Based and Slow-Flow Metrics in Pulmonary Hypertension

Background/Objectives: Pulmonary artery (PA) dilatation and slow-flow are imaging features of pulmonary hypertension (PH), but their quantitative assessment on routine cardiovascular magnetic resonance (CMR) remains limited. This study aimed to develop and evaluate an automated CMR pipeline for quantifying PA size-base...

Khalid Alghamdi, A. Hokmabadi, R. J. van der Geest et al. · 0 citations
Open access Aug 2026

Predictive Power of Pulmonary Artery Stiffness - Right Ventricular Interplay, but not Pulmonary Vascular Resistance, in Mild Pulmonary Hypertension: A PVRI GoDeep meta-registry analysis.

BACKGROUND Pulmonary vascular diseases are characterized by mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR), both reflecting the steady-flow component of right ventricular (RV) afterload while neglecting pulsatile elements. Pulmonary artery compliance (PAC) and arterial elastance (Ea) capt...

A. Yogeswaran, Meike Fünderich, David G. Kiely et al. · 0 citations
Open access Aug 2026

Phase-Resolved Functional Lung MRI-derived Pulmonary Arterial Pulse Wave Velocity Correlates with 12-Month Mortality in Participants with Pulmonary Hypertension: A Post Hoc Analysis of a Multicenter Study.

P pulmonary arterial PWV derived from PREFUL MRI was higher in PH and independently associated with right ventricular function and 12-month mortality, and showed independent associations with right ventricular ejection fraction.

M. M. Klein, A. Voskrebenzev, F. Klimeš et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.